OTCMKTS:PHGUF Pharming Group Q3 2026 Earnings Results & Report $1.26 0.00 (0.00%) As of 11/13/2026 Pharming Group beat analyst earnings expectations and met on revenue in its Q3 2026 results, released October 27, 2026. The company reported EPS of $0.03 versus the $0.0210 consensus estimate, while revenue of $117.60 million matched the $117.60 million estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market Opens Pharming Group EPS ResultsActual EPS$0.03Consensus EPS $0.0210Beat/MissBeat by +$0.0090One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersPharming Group Revenue ResultsActual Revenue$117.60 millionExpected Revenue$117.60 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Pharming Group Q3 2026 Earnings FAQ Did Pharming Group beat earnings estimates for Q3 2026? Pharming Group (OTCMKTS:PHGUF) reported earnings of $0.03 per share for Q3 2026, beating the consensus estimate of $0.0210. The report was announced on Tuesday, October 27, 2026. What was Pharming Group's revenue for Q3 2026? Pharming Group reported revenue of $117.60 million for Q3 2026, against a consensus estimate of $117.60 million. Pharming Group Earnings HeadlinesPharming’s Joenja Approved for Children With APDS in U.K.November 6, 2026 | tipranks.comPharming Group (PHGUF) Q3 2026 Earnings Call Highlights: Revenue Jumps 21% as Rucanest Rebounds ...October 28, 2026 | finance.yahoo.comFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.November 16 at 1:00 AM | Market Tactic (Ad)Pharming Group N.V. Reports Advance In Q3 Bottom LineOctober 28, 2026 | rttnews.comPharming Group lifts Q3 revenues, sharpens guidance as leniolisib program expandsOctober 27, 2026 | tipranks.comPharming Group Q3 Prel. Revenue Rises; Tightens FY26 Revenue GuidanceOctober 22, 2026 | rttnews.comSee More Pharming Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email. Email Address About Pharming GroupPharming Group (OTCMKTS:PHGUF) is a biotechnology company based in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases. Its portfolio includes treatments for hereditary angioedema and activated phosphoinositide 3-kinase delta syndrome (APDS). The company’s products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks, and Joenja (leniolisib), an oral treatment for APDS. Pharming developed Ruconest using a production process involving genetically modified rabbits. Founded in 1988, Pharming serves patients in markets including the United States and Europe, with additional access supported through commercial partners. Its work also includes research and development of medicines for other rare diseases.View Pharming Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.